Epigenomics' 2011 Revenues Fall 22 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that revenues for full-year 2011 dipped 22 percent year over year.

For 2011, the German molecular diagnostics company saw revenues of €1.4 million ($1.9 million) compared to €1.8 million a year ago, a drop-off that Epigenomics attributed to a decline in collaborative income. Sales of its Epi proColon tests were up 38 percent year over year in Europe, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.